Abstract
Research in new treatments for schizophrenia continues. At the same time, increasing numbers of persons with schizophrenia receive their treatment almost exclusively in correctional settings. Though the literature continues to describe this phenomenon in clearer detail, many questions regarding the characteristics of these mentally disordered offenders and their unique treatment needs remain. Research targeting this growing subset of persons with schizophrenia is limited. Risk factors that lead the person with schizophrenia into the correctional system, and whether the offenders with schizophrenia actually differ from non-offenders in terms of their psychopharmacological needs are significant questions that remain unaddressed. Countertransference towards the offender remains a significant issue as well. Given the many limitations on research in this population, pharmacologic strategies for the offender population must be extrapolated from the non-offender population. Traditional depot neuroleptics continue to be underutilized in the treatment of this population. It is argued that both traditional and forthcoming atypical depot neuroleptics may be the best first line agents in this population.
Keywords: Schizophrenia, psychopharmacological, Countertransference, neuroleptics
Current Pharmaceutical Design
Title: Treatment Considerations in the Forensic Patient with Schizophrenia
Volume: 10 Issue: 18
Author(s): David C. Stone and David O. Niz
Affiliation:
Keywords: Schizophrenia, psychopharmacological, Countertransference, neuroleptics
Abstract: Research in new treatments for schizophrenia continues. At the same time, increasing numbers of persons with schizophrenia receive their treatment almost exclusively in correctional settings. Though the literature continues to describe this phenomenon in clearer detail, many questions regarding the characteristics of these mentally disordered offenders and their unique treatment needs remain. Research targeting this growing subset of persons with schizophrenia is limited. Risk factors that lead the person with schizophrenia into the correctional system, and whether the offenders with schizophrenia actually differ from non-offenders in terms of their psychopharmacological needs are significant questions that remain unaddressed. Countertransference towards the offender remains a significant issue as well. Given the many limitations on research in this population, pharmacologic strategies for the offender population must be extrapolated from the non-offender population. Traditional depot neuroleptics continue to be underutilized in the treatment of this population. It is argued that both traditional and forthcoming atypical depot neuroleptics may be the best first line agents in this population.
Export Options
About this article
Cite this article as:
Stone C. David and Niz O. David, Treatment Considerations in the Forensic Patient with Schizophrenia, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384079
DOI https://dx.doi.org/10.2174/1381612043384079 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET
Current Medicinal Chemistry Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Activity of Drugs and Components of Natural Origin in the Severe Myoclonic Epilepsy of Infancy (Dravet Syndrome)
Central Nervous System Agents in Medicinal Chemistry Roles of CLR/RAMP Receptor Signaling in Reproduction and Development
Current Protein & Peptide Science The Medicinal Chemistry Implications of the Anticancer Effects of Aspirin and Other NSAIDs
Mini-Reviews in Medicinal Chemistry Janus Molecule I: Dichotomous Effects of COMT in Neuropathic vs Nociceptive Pain Modalities
CNS & Neurological Disorders - Drug Targets Pre-attentive Visual Processing in Alzheimer’s Disease: An Event-related Potential Study
Current Alzheimer Research Understanding Heterogeneity in Supplementation Effects of Selenium in Men: A Study of Stratification Variables and Human Genetics in a Prospective Sample from New Zealand
Current Pharmacogenomics and Personalized Medicine PEGylated Liposomes Incorporated with Nonionic Surfactants as an Apomorphine Delivery System Targeting the Brain: In Vitro Release and In Vivo Real-time Imaging
Current Nanoscience Effect of Ouabain on the Immune System
Current Hypertension Reviews Differential Effects of Doxazosin on Renin-Angiotensin-System- Regulating Aminopeptidase Activities in Neuroblastoma and Glioma Tumoral Cells
CNS & Neurological Disorders - Drug Targets New Strategies and Patent Therapeutics in EBV-Associated Diseases
Mini-Reviews in Medicinal Chemistry Co-Operation, Compliance, Perseverance: The Finnish Model for Clinical Drug Research
Applied Clinical Research, Clinical Trials and Regulatory Affairs Ribosome Inactivating Proteins (RIPs) from Momordica charantia for Anti Viral Therapy
Current Molecular Medicine Olanzapine v Risperidone: A Contrast Between Atypical Antipsychotics Concerning Control of Schizophrenia
Current Psychopharmacology Moving Beyond Tyrosine Hydroxylase to Define Dopaminergic Neurons for Use in Cell Replacement Therapies for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry Curcumin and Genistein: the Combined Effects on Disease-associated CFTR Mutants and their Clinical Implications
Current Pharmaceutical Design Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Anticancer and Antibacterial Activity of Hyperforin and Its Derivatives
Anti-Cancer Agents in Medicinal Chemistry